In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review Board (PMPRB)—amendments related to new excessive price factors. The decision,…
DIA’s Sorcha McCrohan, contributing to the the August 2024 edition of DIA’s Global Forum magazine, reviews insights from the town hall meetings that brought together regulators from around the world…
Dr David Reddy, Director General, IFPMA, and Dr Bettina Hamelin, President, IMC, jointly advocate for health innovation at the 2025 G7 Summit in Kananaskis (15-17 June). They call G7 leaders…
After 12 years at the helm, Takeda CEO Christophe Weber is stepping down, leaving behind a transformed company. Under his leadership, Japan’s biggest drugmaker expanded globally with the $62 billion…
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. We quickly recognized that the mRNA vaccine approach was potentially ideally suited for the rapid…
Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market…
Susanne Picard, founder and president at SPharm, speaks about how her passion for regulatory affairs led her to found her own consultancy in 1997 and how the company can look…
AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA)…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
The biggest stories coming out of Canadian pharma and healthcare, including AstraZeneca’s acquistion of Canadian biotech Fusion Pharmaceuticals; Valeo Pharma’s new senior executive and board of directors, and generics maker…
See our Cookie Privacy Policy Here
